Miladi-Abdennadher I.,Therapeutic Proteins |
Abdelmaksoud-Dammak R.,Therapeutic Proteins |
Ayed-Guerfali D.B.,Therapeutic Proteins |
Ayadi L.,Habib Bourguiba Hospital of Sfax |
And 8 more authors.
Acta Histochemica | Year: 2012
Cyclo-oxygenase 2 (COX-2) and E-cadherin are promising biomarkers for cancer diagnosis and therapy. The aim of this study was to examine the expression of these two proteins in primary colorectal adenocarcinomas and to investigate their association with clinicopathological characteristics including survival of patients. Immunostaining of E-cadherin and COX-2 was assessed in 70 primary colorectal adenocarcinomas from Tunisian patients. Membranous E-cadherin immunostaining and cytoplasmic COX-2 expression were observed in 74.3% and 68.6% of cases respectively. A significant association was found between COX-2 expression and age at diagnosis (. P=. 0.02), and vessel invasion (. P=. 0.037). The expression of E-cadherin correlated with age at diagnosis (. P=. 0.01), and tumor size (. P=. 0.02). In addition, by multivariate analysis, we revealed a significant association with 1-year disease free survival and a tendency with distant metastasis (. P=. 0.017 and . P=. 0.065 respectively). On the other hand, tumors exhibiting COX-2+/E-cadherin-profile were larger (. P=. 0.006), and in an advanced stage (. P=. 0.001). Survival analysis showed that COX-2 over-expression confers a reduced overall survival rate (. Plog rank. =. 0.036) and is an independent factor predictive for prognosis. © 2011 Elsevier GmbH.
PubMed | Habib Bourguiba Hospital of Sfax
Type: Evaluation Studies | Journal: Journal of applied microbiology | Year: 2010
To study the performance of the CT694 protein in relation to the microimmunofluorescence (MIF) and the pELISA tests for the serodiagnosis of Chlamydia trachomatis infections.The CT694 protein was produced as recombinant protein and was used as antigen in ELISA test for the detection of C. trachomatis IgG antibodies. The performance of the developed ELISA test was compared to the MIF test at two cut-off values of 16 and 64, and to the specific pELISA test using a panel of 342 sera. These sera were from children MIF C. trachomatis and Chlamydophila pneumoniae negative, patients MIF C. pneumoniae positive, patients MIF C. trachomatis positive, patients suspected to have chlamydial infections diagnosed by the Cobas Amplicor test, healthy blood donors and prostitutes. Our results indicate that the developed ELISA test has performed better compared with the MIF and the pELISA tests. The highest performance was obtained when comparing the developed ELISA test in relation to the pELISA, yielding an overall sensitivity and specificity of 85% and 87% respectively.The CT694 ELISA showed the best performance when compared to the species-specific pELISA test and may be used for the serodiagnosis of C. trachomatis infections.The CT694 ELISA test responds to the criteria of both sensitivity and specificity according to the MIF and pELISA tests and may be used for serodiagnosis of C. trachomatis infections.